AI Summary
Helus Pharma reports completion of enrollment in the APPROACH Phase 3 trial for HLP003 in MDD, signaling progress toward topline data in Q4 2026. The program also includes EMBRACE and the EXTEND long-term study, with FDA Breakthrough Therapy Designation supporting potential regulatory progress. Positive Phase 2 durability data and SPRAVATO's sales growth underscore rising interest in innovative depression treatments.
Sentiment Rationale
Completion of Phase 3 enrollment reduces execution risk and sets a clear timeline for topline data, a near-term catalyst likely to attract capital interest. Positive Phase 2 durability and peer demand signals further support upside potential, though execution risk and ultimate NDA success remain.
Trading Thesis
Positive topline data could push HELP higher into 2027; look for pullbacks to buy.
Market-Moving
- Q4 2026 topline readout is the primary near-term catalyst.
- Regulatory timeline to 2028 NDA could drive longer-term upside.
- Positive peer activity in interventional psychiatry may lift sentiment.
Key Facts
- Helus Pharma completes APPROACH Phase 3 enrollment for HLP003 in MDD.
- Topline data expected in Q4 2026; potential FDA NDA in 2028.
- Phase 2 data showed durable efficacy with ~23-point MADRS reduction.
- EMBRACE enrollment ongoing; EXTEND rollover may extend safety/durability data.
- SPRAVATO growth cited as backdrop; Helus aims NSAs as durable depression solutions.
Companies Mentioned
- Helus Pharma (HELP): Announces completion of APPROACH Phase 3 enrollment for HLP003 in MDD; topline data due Q4 2026.
- Johnson & Johnson (JNJ): Cited SPRAVATO sales growth as evidence of demand for novel depression treatments.
- Cybin Inc. (CYBN): Helus Pharma is the commercial operating name of Cybin; potential implications for CYBN stock.
Industry News
Industry News; highlights a clinical development milestone with potential regulatory implications, framing HELP as a developer of innovative NSAs in a fast-evolving depression-treatment landscape.